TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17444850

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 KD) plus ribavirin 600-1000 mg/day
Number of subjects: 201

Group type: COMPARATOR
Intervention: peginterferon alpha-2a plus placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a plus ribavirin 600-1000 mg/day
Number of subjects: 201

Group type: COMPARATOR
Intervention: peginterferon alpha-2a monotherapy
Number of subjects: 201
Study: 15871195

Group type: EXPERIMENTAL
Intervention: Fentanyl 30 microg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 60 microg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 30
Study: 11990805

Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the subthalamic nucleus (STN)
Number of subjects: 12
Study: 9811023

Group type: EXPERIMENTAL
Intervention: octyl‐2‐cyanoacrylate
Number of subjects: 111

Group type: COMPARATOR
Intervention: sutures
Number of subjects: 111
Study: 7645926

Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (MPA) treatment (600, 800, 1200 mg/day or changed dosage)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (MPA) treatment
Number of subjects: 49
Study: 2749132

Group type: EXPERIMENTAL
Intervention: Ocular immunotherapy for 2 years
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo control for 1 year
Number of subjects: 21
Study: 29667870

Group type: EXPERIMENTAL
Intervention: Panic-focused interpretations (PF-interpretations)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-panic-focused interpretations (non-PF-interpretations)
Number of subjects: 65
Study: 27894777

Group type: EXPERIMENTAL
Intervention: Long-acting-release octreotide (20 mg intramuscularly, 2 doses, 4 weeks before and on the day of surgery)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25165165

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant adenovirus serotype 26 HIV-1 vaccine
Number of subjects: 0
Study: 24938136

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40-60 mg/day for 14 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotrophin hormone (40-60 IU every other day for 14 days)
Number of subjects: 92
Study: 23016516

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 24
Study: 19465798

Group type: EXPERIMENTAL
Intervention: 2 g of extra virgin olive oil for 3 months (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 4 g of extra virgin olive oil for 3 months (group B)
Number of subjects: 34
Study: 17504254

Group type: EXPERIMENTAL
Intervention: Segmental ostial pulmonary vein ablation (Group 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Circumferential ablation with PV-LA block (Group 2)
Number of subjects: 73
Study: 15350001

Group type: EXPERIMENTAL
Intervention: Molecular adsorbents recirculating system (MARS) therapy over 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MARS therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: SMT
Number of subjects: 18
Study: 11598598

Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal (156 mg/serving)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-calcium cereal (39 mg/serving)
Number of subjects: 27
Study: 9726182

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 163
Study: 7977479

Group type: EXPERIMENTAL
Intervention: Calcium acetate (CaAC), mean dose 4.1 +/- 0.3 g/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3), mean dose 4.01 +/- 0.8 g/day
Number of subjects: 10
Study: 2658526

Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4611579

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Phenylbutazone (300 mg daily)
Number of subjects: 35
Study: 30635055

Group type: EXPERIMENTAL
Intervention: silybin-phosphatidylcholine complex (45 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: conventional silymarin tablets (70 mg)
Number of subjects: 23
Study: 28411139

Group type: EXPERIMENTAL
Intervention: Hydroquinidine (HQ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25748580

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Tai chi chih (TCC)
Number of subjects: 123
Study: 23582482

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 512

Group type: COMPARATOR
Intervention: control
Number of subjects: 512
Study: 21552061

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 201

Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 201
Study: 18823212

Group type: EXPERIMENTAL
Intervention: Aural presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Number of subjects: 0
Study: 16284796

Group type: EXPERIMENTAL
Intervention: Somatostatin prophylaxis (somatostatin(+))
Number of subjects: 23

Group type: COMPARATOR
Intervention: No somatostatin prophylaxis (somatostatin(-))
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PPPD surgery
Number of subjects: 23
Study: 11854938

Group type: EXPERIMENTAL
Intervention: Individualized teaching program during hospitalization, followed by 12 weeks of supportive care via telephone or mail
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Individualized teaching program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no individualized teaching program)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 10673994

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infusional 5-FU therapy (B1, B2, B3 regimens)
Number of subjects: 0
Study: 8578185

Group type: EXPERIMENTAL
Intervention: Perendoscopic hemostasis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Omeprazole infusion
Number of subjects: 42
Study: 2349923

Group type: EXPERIMENTAL
Intervention: 80 micrograms copper sulfate.kg body wt‐1.d‐1
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 101071

Group type: EXPERIMENTAL
Intervention: Glucose with essential amino acids (21 g/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose with essential and nonessential amino acids (21 g/day each)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 6
Study: 29324595

Group type: EXPERIMENTAL
Intervention: Antimuscarinic therapy (4-8 mg daily)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645
Study: 27402817

Group type: EXPERIMENTAL
Intervention: Addition of atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switch from lopinavir/ritonavir to atazanavir/ritonavir
Number of subjects: 0
Study: 24090619

Group type: EXPERIMENTAL
Intervention: Alcohol dependence (AD) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-occurring alcohol dependence and PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0
Study: 22147471

Group type: EXPERIMENTAL
Intervention: HSA‐GnRH with FCA
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: DD+MO
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: DD+FIA
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: OA‐GnRH
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: KL‐GnRH
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: HSA‐GnRH
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 3-booster immunizations against GnRH conjugated to OA
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (immunized against OA)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 2-booster immunizations against GnRH conjugated to OA
Number of subjects: 156
Study: 20688622

Group type: COMPARATOR
Intervention: L-thyroxine (L-T4)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) + L-triiodothyronine (L-T3)
Number of subjects: 36
Study: 18287255

Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 2 weeks
Number of subjects: 324

Group type: COMPARATOR
Intervention: Darbepoetin alfa once weekly
Number of subjects: 324
Study: 15702319

Group type: EXPERIMENTAL
Intervention: Prophylactic lowering of intraocular pressure (IOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 0
Study: 15190655

Group type: EXPERIMENTAL
Intervention: Complementary Medicine (CM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 43
Study: 11045391

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nifedipine/Felodipine
Number of subjects: 11
Study: 9367398

Group type: EXPERIMENTAL
Intervention: nhuIL-2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: IVIG infusions during placebo phase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IVIG infusions during nhuIL-2 treatment phase
Number of subjects: 10
Study: 1487553

Group type: EXPERIMENTAL
Intervention: Synthroid (600 micrograms)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Levoxine (600 micrograms)
Number of subjects: 30
Study: 3895987

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31120574

Group type: EXPERIMENTAL
Intervention: Autologous BMDMSCs
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pooled-allogeneic BMDMSCs
Number of subjects: 8
Study: 29436333

Group type: EXPERIMENTAL
Intervention: Group singing workshops for 10 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Group play workshops for 10 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 26538428

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (PGx)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 179
Study: 24704737

Group type: EXPERIMENTAL
Intervention: Eye tracking only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal debrief only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined verbal debrief and eye tracking
Number of subjects: 0
Study: 22685047

Group type: EXPERIMENTAL
Intervention: 7 g dark chocolate daily for 7 weeks
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (n=70)
Number of subjects: 194
Study: 20194880

Group type: EXPERIMENTAL
Intervention: Simple stenting strategy (n=250), main vessel stented with optional kissing balloon dilatation/T-stent.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Complex stenting strategy (n=250), both vessels systematically stented with mandatory kissing balloon dilatation.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Simple stenting strategy (n=250).
Number of subjects: 500

Group type: COMPARATOR
Intervention: Complex stenting strategy (n=250).
Number of subjects: 500
Study: 17875243

Group type: EXPERIMENTAL
Intervention: PR-melatonin (Circadin* 2 mg), one tablet per day at 2 hours before bedtime
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PR-melatonin (Circadin* 2 mg)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 15937634

Group type: EXPERIMENTAL
Intervention: RT+WLoss (n=16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: WLoss (n=13)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RT+WLoss (n=14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: WLoss (n=12)
Number of subjects: 36
Study: 12090325

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day) and azathioprine (100 mg/day) for four months
Number of subjects: 43

Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 43
Study: 10319774

Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil/nitrous oxide anesthesia with bispectral index monitoring
Number of subjects: 274

Group type: COMPARATOR
Intervention: Propofol/alfentanil/nitrous oxide anesthesia without bispectral index monitoring
Number of subjects: 274
Study: 8969780

Group type: EXPERIMENTAL
Intervention: Transient hyperemic response test (carotid artery compression)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Leg‐cuff test
Number of subjects: 11
Study: 1370924

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: t‐PA (60 mg in the first hour and a maintenance infusion of 13.3 mg/hr for 3 hours)
Number of subjects: 12
Study: 6376145

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide (meal + glipizide)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (meal alone)
Number of subjects: 10
Study: 30616537

Group type: EXPERIMENTAL
Intervention: Individually tailored counselling for an active life (one face-to-face session, four phone calls, and supportive written material)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Written general health information only
Number of subjects: 200
Study: 29528963

Group type: EXPERIMENTAL
Intervention: 6-month healthy lifestyle intervention (telephone-based coaching service)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 27620884

Group type: EXPERIMENTAL
Intervention: Surgical glove (SG) compression therapy on the dominant hand
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control hand (non-dominant hand without SGs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Surgical glove (SG) compression therapy
Number of subjects: 42
Study: 24146180

Group type: EXPERIMENTAL
Intervention: Open nostril
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nostril occlusion
Number of subjects: 32
Study: 22241317

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 63
Study: 19544389

Group type: EXPERIMENTAL
Intervention: New method for determining cup orientation in THA using a fully automated registration procedure.
Number of subjects: 407
Study: 16420199

Group type: EXPERIMENTAL
Intervention: Uppermost quartile of weight
Number of subjects: 7523

Group type: EXPERIMENTAL
Intervention: Top quartile of weight gain since age 25
Number of subjects: 7523

Group type: EXPERIMENTAL
Intervention: Top quartile of percentage of body fat
Number of subjects: 7523
Study: 15685469

Group type: EXPERIMENTAL
Intervention: Group 2 (FNS-IM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Group 1 (no FNS)
Number of subjects: 16
Study: 11387579

Group type: EXPERIMENTAL
Intervention: Percutaneous neuromuscular electric stimulation (perc‐NMES)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transcutaneous neuromuscular electric stimulation (trans‐NMES)
Number of subjects: 10
Study: 9422897

Group type: EXPERIMENTAL
Intervention: 60% xenon
Number of subjects: 54

Group type: COMPARATOR
Intervention: 60% nitrous oxide with 0.7% sevoflurane
Number of subjects: 54

Group type: COMPARATOR
Intervention: 60% nitrous oxide with 0.5% isoflurane
Number of subjects: 54
Study: 8498150

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3302924

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg every six hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30001572

Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (FTG and CON)
Number of subjects: 30
Study: 27502847

Group type: EXPERIMENTAL
Intervention: Mobile-based interventions for clinicians
Number of subjects: 9600

Group type: COMPARATOR
Intervention: Routine practice pattern (Control)
Number of subjects: 9600
Study: 23959376

Group type: EXPERIMENTAL
Intervention: Desensitizing agent (5% potassium nitrate, 2% sodium fluoride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22633517

Group type: EXPERIMENTAL
Intervention: Prophylactic fluconazole
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Baseline colonisation
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Acquired colonisation
Number of subjects: 336
Study: 20038231

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study: 18402848

Group type: EXPERIMENTAL
Intervention: Unlimited free emergency contraceptive pills (ECPs) in advance of need
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills (ECPs)
Number of subjects: 148
Study: 20635134

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control 15/min paced breathing (n = 5)
Number of subjects: 11
Study: 15806544

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day) plus antibiotics
Number of subjects: 66

Group type: COMPARATOR
Intervention: Antibiotics without G-CSF
Number of subjects: 66
Study: 11940025

Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation (TES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive placebo
Number of subjects: 0
Study: 9604730

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg ampul in 100 ml given intravenously in 15 min doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tramadol and Placebo
Number of subjects: 12
Study: 7798465

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 16
Study: 3071619

Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg twice a day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg 3 times a day
Number of subjects: 19
Study: 11230635

Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 mol/L) injected intravenously at doses of 0.1 or 0.3 mmol/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 mol/L) injected intravenously
Number of subjects: 21
Study: 29873107

Group type: EXPERIMENTAL
Intervention: Pankowska Equation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Carbohydrate counting
Number of subjects: 33

Group type: COMPARATOR
Intervention: Food Insulin Index
Number of subjects: 33
Study: 27245553

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study: 25036731

Group type: EXPERIMENTAL
Intervention: TRP-rich diet (TRP+); 9 BDs, 11 NBDs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control diet (CTR); 10 BDs, 11 NBDs
Number of subjects: 41
Study: 22086879

Group type: EXPERIMENTAL
Intervention: Active pacing (dual-chamber pacing at 70 bpm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Backup pacing (atrial pacing at 30 bpm)
Number of subjects: 80
Study: 20563820

Group type: COMPARATOR
Intervention: Conventional radiographs (CR)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 33
Study: 19089749

Group type: EXPERIMENTAL
Intervention: Coffeeberry (CB) supplementation at a dose of 800 mg per day for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coffeeberry (CB) supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P) group
Number of subjects: 20
Study: 15996846

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2a: lesions <5 mm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2b: lesions 5-9 mm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2c: lesions >9 mm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 100
Study: 12453951

Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 10361754

Group type: EXPERIMENTAL
Intervention: Breastfeeding education (face-to-face after delivery and during follow-up for 4 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no breastfeeding education)
Number of subjects: 120
Study: 7479216

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: No erythropoietin treatment
Number of subjects: 30
Study: 2320950

Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 453783

Group type: EXPERIMENTAL
Intervention: Intravenously administered glycopyrrolate 0.2 mg (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orally given analgesic-spasmolytic combination preparation (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no medication, Group III)
Number of subjects: 30
Study: 31658289

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 41430

Group type: COMPARATOR
Intervention: DPP4 inhibitors
Number of subjects: 41430
Study: 29894994

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Histological tissue sample analysis (gold standard)
Number of subjects: 25
Study: 27719703

Group type: EXPERIMENTAL
Intervention: Virtual group (16 patients) using computer-aided surgical simulation procedure
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (19 patients) using traditional model surgery based on plaster casts
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison between virtual group and control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35